Shweta Singh Maniar
About Shweta Singh Maniar
Shweta Singh Maniar is an independent Class II director at RxSight, Inc., age 41 as of the 2025 annual meeting, serving since December 2021 with a background in health tech strategy and biopharma commercialization . She holds a B.A. in Economics from the University of California, San Diego and currently leads Google Cloud’s Healthcare & Life Sciences Solutions & Strategy, bringing domain expertise in medtech and data-driven healthcare to the board . She is deemed independent under Nasdaq rules .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Google (Google Cloud) | Global Leader, Healthcare & Life Sciences Solutions & Strategy | Since July 2018 | Leads vision, strategy, and go-to-market for industry product strategy |
| Genentech | Executive leading market growth strategies for therapies/diagnostics | Nov 2013 – June 2018 | Technology accelerator focus in biopharma |
| Summa Health | Director, Center of Minimally Invasive Therapeutics | More than one year (dates not disclosed) | Focus on minimally invasive therapeutics |
| Cleveland Clinic; Austen BioInnovation Institute | Research roles | Several years (dates not disclosed) | Medical devices and minimally invasive therapeutics |
External Roles
| Organization | Role | Tenure | Committees/Notes |
|---|---|---|---|
| Orthofix Medical Inc. (NASDAQ:OFIX) | Director | Current | Nominating, Governance & Sustainability Committee; Independent |
Board Governance
- Committee assignments: Member, Corporate Governance and Nominating Committee; chair is Robert Warner .
- Independence: Board determined Maniar is “independent” under Nasdaq rules .
- Attendance: In FY2024 the board held five meetings; each director attended at least 75% of board and committee meetings; same standard met in FY2023 when the board held six meetings .
- Board leadership: Separate Chair (J. Andy Corley) and CEO (Ron Kurtz) roles, supporting independent oversight .
Fixed Compensation
| Year | Board Cash Retainer ($) | Committee Membership Cash ($) | Total Cash ($) | Policy Reference |
|---|---|---|---|---|
| 2024 | 50,000 | 5,000 (Governance Committee member) | 55,000 | Policy effective Jan 1, 2024 increased board cash to $50,000; committee member fee $5,000 |
| 2023 | 45,000 | 5,000 (Governance Committee member) | 50,000 | Policy for 2023 board cash $45,000; committee member fee $5,000 |
- RxSight’s Outside Director Compensation Policy specifies: $50,000 annual board retainer (2024+), $5,000 Governance Committee member, with additional chair and audit/compensation fees; $1,500 per meeting beyond eight/year . In 2023, board retainer was $45,000; same committee fee schedule applied .
Performance Compensation
| Year | Stock Awards ($) | Award Type | Annual Grant Value Policy | Vesting Schedule | Change-in-Control / Death/Disability Treatment |
|---|---|---|---|---|---|
| 2024 | 149,945 | Time-based RSUs (2021 Plan) | Annual RSU grant value $150,000 (pre–Dec 19, 2024) | Annual Award vests in full by next annual meeting or one-year anniversary, subject to continued service | |
| 2023 | 149,980 | Time-based RSUs (2021 Plan) | Annual RSU grant value $150,000 | Annual Award vests in full by next annual meeting or one-year anniversary, subject to continued service | |
| Policy Update (Dec 19, 2024) | — | RSUs (no ISOs) | Annual RSU grant value increased to $170,000; Initial RSU grant value increased to $277,500 | Initial Award vests 1/3 annually on each anniversary of start date | Full vesting of outstanding director equity upon change-in-control; full vesting upon death or disability |
- Performance metrics for director equity: None disclosed; director equity is time-based RSUs (no performance conditions) .
Other Directorships & Interlocks
- Orthofix directorship indicates healthcare network connectivity (orthopedics vs. ophthalmology, not a direct competitor) .
- Interlock: RxSight director Julie B. Andrews is the CFO of Orthofix; this creates cross-company board/management ties, potentially enhancing information flow and governance perspective across medtech subsectors .
Expertise & Qualifications
- Healthcare technology leadership (Google Cloud), biopharma commercialization (Genentech), and medtech research experience (Cleveland Clinic/Austen BioInnovation Institute), supporting RxSight’s strategy execution and digital/AI considerations in ophthalmic devices .
- Education: B.A., Economics, University of California, San Diego .
Equity Ownership
| Date/Year | Common Shares Owned | Unvested RSUs Outstanding | Beneficial Ownership % | Notes |
|---|---|---|---|---|
| Apr 8, 2025 snapshot | 4,829 | 2,554 (RSUs vesting within 60 days) | <1% | From 2025 proxy summary via public posting |
| Dec 31, 2024 | — | 8,953 | — | RSUs outstanding as of year-end |
| Dec 31, 2023 | — | 18,529 | — | RSUs outstanding as of year-end |
| Apr 8, 2024 snapshot | — | 5,731 (RSUs vesting within 60 days) | <1% | Beneficial ownership table shows <1% for Maniar |
- Hedging/pledging: Company policy prohibits hedging and pledging of RxSight securities for directors and employees .
- Stock ownership guidelines: Non-employee directors should hold shares equal to 3x annual cash retainer, with compliance timing until the later of Jan 1, 2028 or five years from appointment; retention of 50% of net shares if below guideline .
Governance Assessment
-
Board effectiveness signals:
- Independence, Governance Committee role, and the board’s separation of Chair/CEO support oversight quality .
- Attendance meets the 75% threshold, indicating engagement .
- Say-on-pay approval of ~95.3% (2024) suggests broader investor confidence in governance and pay practices, though this vote covers executive compensation .
-
Alignment and incentives:
- Director pay skews to equity via annual RSUs, aligning with shareholder value; policy increased annual RSU value to $170,000 effective Dec 19, 2024, further emphasizing equity alignment .
- Ownership guidelines require meaningful shareholding, but specific compliance status for Maniar is not disclosed .
-
Conflicts and related-party exposure:
- No related-party transactions disclosed involving Maniar at RxSight; related-party issues disclosed pertain to another director (Dr. Link) .
- External board role at Orthofix is non-competitive with RxSight’s ophthalmology focus; interlock with Julie Andrews (Orthofix CFO and RxSight director) increases network ties without evident conflict .
-
Risk indicators and red flags:
- OFIX disclosed a late Form 4 filing for Shweta Singh Maniar for a March 10, 2023 sale (filed sixteen business days late), indicating a one-off reporting timeliness issue in her external role; no comparable RxSight Form 4 details were disclosed in RxSight proxies .
- Limited disclosed common-share ownership at RxSight (<1% beneficial ownership) implies modest “skin in the game,” though RSU holdings and guidelines may build alignment over time .
- Hedging/pledging prohibited by policy, mitigating alignment risks .
Overall: Maniar’s independence, governance committee service, and attendance support board effectiveness. Her health-tech and biopharma background is additive for RxSight’s growth stage. Equity-heavy director pay and ownership guidelines should improve alignment; no RxSight-specific related-party conflicts identified. Monitor any future late filings at external boards and track progress toward ownership guideline compliance .